StreetAlpha.app
Home › Stocks › LPCN

Lipocine Inc. (LPCN)

$1.48
▼ −1.33%
LAST CLOSE · NOV 20

Lipocine is a biopharmaceutical company that develops oral drugs, with its lead product TLANDO licensed to partners for testosterone therapy. It last closed at $1.48 on Nov 20, down 1.33% on the day. The next earnings report for LPCN is expected around Wed, Feb 17, 2027. For the quarter ended Sep 2026, LPCN reported EPS of -$0.08 on revenue of $2.3M, with revenue up 1898.8% from a year ago. Over its last 8 reports the stock moved an average of 3.3% the session after earnings. Over the last 12 months LPCN insiders bought $821K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is LPCN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LPCN.

Key Stats

Last 12 months
Results
Revenue
$3.7M
−13.4% vs a year ago
Net income
−$9.3M
−249.2% margin
EPS (diluted)
−$1.28
Operating margin
−269.1%
−$10.1M operating income
Valuation
Market cap
$16.4M
11.1M shares
P/E
–
No P/E while losing money
Price to sales
4.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.6M
At Sep 30
Shareholder equity
$21.2M
Shares outstanding
11.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $16.1M$16.1MFY2021FY2022: $500K$500KFY2022FY2023: −$2.9M−$2.9MFY2023FY2024: $11.2M$11.2MFY2024FY2025: $2.0M$2.0MFY2025

From LPCN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 17
Estimated date · Time not announced
Reported EPS
-$0.08
Quarter ended Sep 2026
Year ago EPS
-$0.59
Same quarter last year
Revenue
$2.3M
+1898.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Mar 2025: -$0.35Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.59Sep '25Dec 2025: -$0.34Dec '25Mar 2026: -$0.54Mar '26Jun 2026: -$0.32Jun '26Sep 2026: -$0.08Sep '26Latest -$0.08
Revenue by quarter
Dec 2024: $3.5MDec '24Mar 2025: $93,864Mar '25Jun 2025: $622,849Jun '25Sep 2025: $114,574Sep '25Dec 2025: $1.1MDec '25Mar 2026: $119,397Mar '26Jun 2026: $190,099Jun '26Sep 2026: $2.3MSep '26Latest $2.3M
How LPCN moved after its last 8 reports
Average move the session after a report ±3.3%
Nov 5, 2026Time not announced+6.3%
Aug 4, 2026Time not announced+0.9%
May 7, 2026Time not announced−1.6%
Feb 18, 2026Time not announced−1.3%
Nov 6, 2025Time not announced+3.1%
Aug 5, 2025Time not announced−1.6%
Mar 7, 2024Time not announced+1.4%
Jan 25, 2021After the close−10.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LPCNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LPCN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LPCN

Technical Analysis

LPCN · as of the Nov 20 close · updated each morning
Downtrend

The stock is 4% below its 20 day and 20% below its 50 day average. It is 123% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot S1 at $1.41, and the nearest resistance the 20 day average at $1.54.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 8.8%/day
Key levels
$12.3752 week high+735.8%
$3.31200 day average+123.6%
$2.00100 day average+35.1%
$1.7850 day average+20.3%
$1.56Swing high (Oct 29)+5.4%
$1.55Pivot R1+4.7%
$1.5420 day average+4.1%
$1.48Pivot+0.0%
$1.48Last close
$1.41Pivot S1−4.7%
$1.40Swing low (Oct 19)−5.4%
$1.3652 week low−8.1%
Indicators
RSI (14)40.26Middle of its rangeNeutral
MACD-0.05Above its signal lineBullish
Stochastic33.3Middle of its rangeNeutral
ADX (14)12.2No clear trend
Williams %R-77.2Oversold below −80, overbought above −20Neutral
CCI (20)-52.5Oversold below −100, overbought above 100Neutral
Rate of change−5.7%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 8.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LPCN

What happened before

See how LPCN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LPCN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LPCN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LPCNHow many large options trades hit LPCN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

LPCN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼8 buying vs 10 selling
  • ▼Held by funds -0.8 pts
  • ▲Funds holding +1
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3837+2.7%
In funds' top 1000–
Held by funds26.1%26.9%−0.8 pts
New / increased2 / 65 / 14−57.9%
Reduced / sold out9 / 13 / 15−44.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LPCN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LPCN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$821K8 buys · 2 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $305K between Nov 12 and Nov 20.
2026-04 bought $435K2026-09 bought $82K2026-11 bought $305KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 20John W. HiguchiDirectorBuy150,000$1.50$225K
Nov 13Mahesh V. PatelCEOBuy50,000$1.59$79K
Sep 30John W. HiguchiDirectorBuy25,007$2.20$55K
Sep 28John W. HiguchiDirectorBuy12,561$2.16$27K
Apr 7John W. HiguchiDirectorBuy40,000$2.03$81K
Apr 6Mahesh V. PatelCEOBuy25,000$2.03$51K
Every insider buy and sale for LPCN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LPCN insider trades →

From SEC Form 4 filings by LPCN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LPCN is in one of them and how their past LPCN trades turned out.

LPCN in the AI portfolios
Loading…

LPCN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LPCN in an article yet. Here's the latest on the wider market.

LPCN in the news

About Lipocine

Lipocine is a biopharmaceutical company based in Salt Lake City, United States. It uses its own technology to develop medicines taken by mouth, including drugs that the body does not absorb well in standard form. Its lead product, TLANDO, is an oral treatment for testosterone deficiency in adult men, and partner companies sell it to patients in several countries. The company also develops candidates for brain and nervous system conditions, liver disease, and hormone treatments.

Headquarters
Salt Lake City